00085472can171701-sup-184506_2_supp_4247414_zvm4z1_eps_zip.zip (87.54 kB)

Supplementary Table 1 from Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer

software

posted on 2023-03-31, 01:10 authored by Jonathan T. Goldstein, Ashton C. Berger, Juliann Shih, Fujiko F. Duke, Laura Furst, David J. Kwiatkowski, Andrew D. Cherniack, Matthew Meyerson, Craig A. Strathdee

Chemical structures of compounds used in study

Funding

Bayer AG

National Cancer Institute

History

ARTICLE ABSTRACT

The PPARG gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the RXRA gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of PPARG or RXRA lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. Cancer Res; 77(24); 6987–98. ©2017 AACR.